Eon Labs Schedules Fourth Quarter and Full Year 2004 Results Release a

    Pharmaceutical Writers/Business Editors/Health Editors

    LAKE SUCCESS, N.Y.--(BUSINESS WIRE)--Feb. 18, 2005--Eon Labs, Inc. (Nasdaq: ELAB) will release fourth quarter and full year 2004 results on Tuesday, March 1, 2005, before the market opens. The Company will hold a conference call and audio webcast to discuss results at 10 a.m. Eastern Time that day.
    To access the audio webcast, visit the Investor Relations section of the Eon Labs, Inc. website at www.eonlabs.com on March 1 and follow the link.
    To access the conference call dial toll free (800) 811-0667, or (913) 981-4901 for international callers, five minutes before the teleconference. The password for the conference call is "ELAB."
    A replay of the conference call will be available until 5 p.m. Eastern Time on March 7, by calling toll free (888) 203-1112, or (719) 457-0820 for international callers. The passcode for the replay is 4485337. The replay will also be available on the Investor Relations section of the Eon Labs, Inc. website, www.eonlabs.com.

    Eon Labs is a generic pharmaceutical company specializing in developing, licensing, manufacturing, selling and distributing a broad range of prescription pharmaceutical products. For press releases and other company information, visit the Eon Labs, Inc. website at www.eonlabs.com.

    Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

--30--KL/ny*

CONTACT: Eon Labs, Inc. Christopher LoSardo, 516-478-9712

KEYWORD: NEW YORK INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY EARNINGS CONFERENCE CALLS SOURCE: Eon Labs, Inc.

Copyright Business Wire 2005